Abstract  We hit derivative sets of manlike monoclonal antibodies by fusing lymphocytes from cancer patients with a manlike lymphoid line,
LICR-LON/HMy2. Two antibodies, LGL1.1D6 and LLU6.3A4, derivative from patients with glioma and bronchial carcinoma respectively,
were designated for clinical think on the foundation of protection patterns in radioimmunoassays with growth radiophone lines and localisation
of manlike growth xenografts. Highly pure monoclonal antibodies were embattled using magnitude supernatants from hybridomas grown
in humour liberated medium. After radiolabelling with131I, 1 mg antibody was injected intravenously into patients with modern glioma and carcinoma of the bronchus. Good localisation
was obtained in fivesome discover of octad patients with glioma and fivesome discover of heptad patients with carcinoma of the bronchus. Despite
the theoretical difficulties inexplicit in the creation of manlike monoclonal antibodies this think demonstrates their potential
for the clinical fix of solidified tumours.

Content Type Journal ArticleCategory ArticlesDOI 10.1007/BF02934852Authors
Karol Sikora, Ludwig Institute for person Research, MRC Centre Hills Road metropolis UKThomas Alderson, Ludwig Institute for person Research, MRC Centre Hills Road metropolis UKAnthony Nethersell, Ludwig Institute for person Research, MRC Centre Hills Road metropolis UKHoward Smedley, Ludwig Institute for person Research, MRC Centre Hills Road metropolis UK

Journal Medical OncologyOnline ISSN 1559-131XPrint ISSN 1357-0560

Journal Volume Volume 2

Journal Issue Volume 2, Number 2 / June, 1985 (Source: Medical Oncology)

Tags: Cancer, glioma, Journal Medical